PHE - Corporate - A Clinical and Cost Effectiveness Model on Formalising New-born Screening for β-thalassaemia Major
Estimated value
—
Awarded value
£81k
Awarded 30 Oct 2020
Suppliers
1
Lots
1
1 awarded
Published
03 Nov 2020
Deadline 14 Oct 2020
Description
Commissioning document: Formalising screening for β-thalassaemia major as part of the newborn blood spot screening programme for sickle cell disease: a clinical and cost-effectiveness model
Scope
- Reference
- tender_251184/899984
- Commercial tool
- Standalone contract
- Contract dates
- 02 Nov 2020 to 28 Apr 2022
- CPV classifications
- 75122000
- Particular suitability
- Small and medium-sized enterprises (SME)
Submission & procedure
- Submission deadline
- 14 Oct 2020, 11:00 am
Award details
Awarded supplier(s), contract period and value as published in the award notice.
Awarded value
£81k
Award date
30 Oct 2020
Contract start
02 Nov 2020
Contract end
28 Apr 2022
Awarded to